Skip to content

Vera Therapeutics VERA Return on equity

Return on equity at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
24.2%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-706%-1,302pp
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
65%+53.8pp
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-53.6%-22.6pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-58.1%+7.9pp
Immunome logo
ImmunomeIMNM
-50.1%-10.8pp

Other financials

Income statement

See full
Operating income-$125.1M-119%
Net income-$121.0M-134%
EPS (diluted)-$1.69-109%

Balance sheet

See full
Cash & equivalents$114.4M+108%
Total debt$75.0M+37.8%
Total equity$499.7M-6.6%
Total assets$621.7M+1.9%

Cash flow

See full
Operating cash flow-$106.5M-95.8%
CapEx$23.0K-87.7%
Free cash flow-$106.5M-95.1%

Valuation

See full
Market cap$2.74B+87.5%
Enterprise value$2.7B+85.0%

Returns & leverage

See full
Debt / equity0.2×0.0×
Current ratio13.6×-14.0×

Where this comes from

Calculated from Vera Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vera Therapeutics's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vera Therapeutics's return on equity?
Vera Therapeutics (VERA) reported return on equity of -71.3% in Q1 2026.
How has Vera Therapeutics's return on equity changed year-over-year?
Vera Therapeutics's return on equity decreased by 80.6% year-over-year, from -39.5% to -71.3%.
What is the long-term trend for Vera Therapeutics's return on equity?
Over 3 years (2022 to 2025), Vera Therapeutics's return on equity has grown at a -25.3% compound annual growth rate (CAGR), from -121.6% to -50.7%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.